Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.38 | 1.36 |
NAV | ₹135.93 | ₹203.53 |
Fund Started | 12 Feb 2007 | 07 May 2007 |
Fund Size | ₹60385.03 Cr | ₹89383.23 Cr |
Exit Load | Exit load for units in excess of 10% of the investment,1% will be charged for redemption within 365 days | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 0.06% | 5.94% |
3 Year | 20.08% | 24.58% |
5 Year | 23.00% | 26.08% |
1 Year
3 Year
5 Year
Equity | 98.88% | 93.94% |
Cash | 1.12% | 6.06% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Fortis Healthcare Ltd. | 4.19% |
GE Vernova T&D India Ltd | 3.95% |
Mphasis Ltd. | 3.02% |
Dixon Technologies (India) Ltd. | 2.83% |
Vishal Mega Mart Ltd. | 2.66% |
Ipca Laboratories Ltd. | 2.53% |
JK Cement Ltd. | 2.50% |
Indian Bank | 2.42% |
Bharat Electronics Ltd. | 2.37% |
Oberoi Realty Ltd. | 2.36% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.46% |
AU Small Finance Bank Ltd. | 3.70% |
Indian Bank | 3.54% |
The Federal Bank Ltd. | 3.38% |
Balkrishna Industries Ltd. | 3.37% |
Fortis Healthcare Ltd. | 3.19% |
Coforge Ltd. | 3.11% |
Hindustan Petroleum Corporation Ltd. | 2.96% |
Glenmark Pharmaceuticals Ltd. | 2.67% |
Ipca Laboratories Ltd. | 2.52% |
Name | Pankaj Tibrewal | Chirag Setalvad |
Start Date | 07 Sep 2022 | 28 Jun 2014 |
Name
Start Date
Description | The scheme seeks to generate long-term capital appreciation from a portfolio of equity and equity related securities, by investing predominantly in mid companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 12 Feb 2007 | 07 May 2007 |
Description
Launch Date